306 results about "A549 cell" patented technology

The invention discloses polypeptide for specifically targeting a lung cancer cell and an application thereof. The polypeptide for specifically targeting the lung cancer cell has an amino acid sequence shown as SEQ ID NO.1, and is prepared by screening on the surface of the human lung cancer cell by an ex-vivo bacterial random polypeptide library exhibiting method and a flow cell sorting method. The polypeptide for specifically targeting the lung cancer cell can be applied to preparation of lung cancer diagnosing tracer, lung cancer cell detecting reagent and the like. The polypeptide for specifically targeting the lung cancer cell can be combined with a lung cancer A549 cell specifically, is not combined with a normal lung cell and other tumor cells; and the preparation method is simple, feasible and applicable to large-scale industrial production. The polypeptide for specifically targeting the lung cancer cell provides important theoretical and practical basis for early diagnosis, targeting therapy of the lung cancer and the like, and has a wide application prospect.

The invention discloses a triphenylphosphine-polyethyleneglycol 1000 vitamin E succinate (TPGS 1000-TPP) conjugated compound, and a preparation method and application thereof. The structural formula of the compound is disclosed as Formula I. The preparation method of the conjugated compound comprises the following steps: (1) reacting triphenylphosphine and 6-bromocaproic acid to obtain 5-carboxyamyltriphenylphosphonium bromide disclosed as Formula IV; and (2) carrying out esterification reaction on the 5-carboxyamyltriphenylphosphonium bromide disclosed as Formula IV and polyethyleneglycol 1000 vitamin E succinate to obtain the conjugated compound disclosed as Formula I. The invention also discloses a mitochondrion targeted taxol liposome comprising the conjugated compound. The drug effect test proves that the mitochondrion targeted taxol liposome has strong cell toxicant action in the in-vitro cell experiment and in-vivo transplantation tumor model of human lung adenocarcinoma A549 cells and drug-resistant A549 / cDDP cells thereof and can enhance the antitumor effect of taxol on drug-resistant A549 / cDDP cells.

The invention discloses a method for culturing lung cancer stem cells under 3D culture conditions and belongs to the field of cell culture methods. The method comprises the following steps of placing human lung adenocarcinoma cell line A549 in an incubator for culturing with a RPMI-1640 complete culture medium containing 10% fetal calf serum, taking a cell suspension in a logarithm growth period, adjusting the concentration of the cells to 5*10<4>cells / ml and adding 200 mu L / well into a 96-well plate in which 50 mu L / well BME is spread; on the third day, changing the culture medium for the A549 cells with a RPMI-1640 complete culture medium containing IGF-1 and FGF and further culturing; digesting BME through a proteolytic enzyme, recovering the A549 cells from a recovery liquid and finally identifying the cells. By such design, the A549 cells form cloned mass similar to in-vivo tumor mass in vitro, which is closer to the three-dimensional growth state in the human body and thus the stable separation and effective amplification of stem cells are achieved. The cancer stem cells capable of resisting anticancer drugs are screened.

The invention provides a new use of beta-sitosterol in preparation of a medicine for treating or preventing influenza A, and further provides the medicine for treating or preventing the influenza A. The medicine comprises an active component of the beta-sitosterol. The inventor of the application finds that the beta-sitosterol has a significant inhibitory activity for an inflammatory reaction mediated by influenza A virus. The fluorescence real-time quantitative polymerase chain reaction (PCR) is used for confirming that the beta-sitosterol can obviously inhibit abnormal expressions of A549 inflammatory cytokines infected by an H1N1 virus and show a dose-dependent relationship; the Western blotting is adopted to confirm that the beta-sitosterol can inhibit activation with host inflammation related signaling pathways and show the dose-dependent relationship. Animal experiments show that the beta-sitosterol can significantly inhibit lung injuries and inflammations induced by influenza virus A (H1N1).

The present invention provides methods for adapting cells, such as A549 cells, to growth in serum-free and animal material-free medium suspension culture. The present invention provides methods for preparing viruses, such as adenovirus, from the A549 cells adapted for growth in serum-free and animal material-free medium in suspension culture.

The invention provides an anti-tumor metal iridium (III) complex, belonging to the technical field of biological medicine. The chemical formula of the anti-tumor metal iridium (III) complex is [Ir(ppy)2(BDPIP)]PF6. Furthermore, the invention also provides a preparation method of the anti-tumor metal iridium (III) complex and application of the anti-tumor metal iridium (III) complex in anti-tumor drugs. The anti-tumor metal iridium (III) complex has a very strong inhibiting effect for the growth of tumor cells, especially for the growth of cells A549, can induce the apoptosis of the tumor cells, has an IC50 value of 3.6mu M, and can be used as a medicine for treating tumor A549; in vivo tests prove that the tumor inhibiting rate of the anti-tumor metal iridium (III) complex reaches up to 63.84%. The preparation method of the metal iridium (III) complex is high in yield.

The invention discloses a conjugate of curcumin and an oligopeptide Arg-Gly-Asp-Ser, a preparation method of the conjugate and the tumor cell proliferation resisting activity, the A549 cell migration and invasion inhibiting effects, the S180 tumor-bearing mouse tumor weight increasing inhibiting activity, the Lewis lung cancer metastasis inhibiting activity, the xylene-induced mouse ear swelling inhibiting activity and the rat thrombus generation inhibiting activity of the conjugate. The conjugate has the following formula (please see the formula in the description).

The invention discloses enzymolysis polypeptide and use thereof in preparation of a medicine for treating lung adenocarcinoma. The enzymolysis polypeptide is prepared from cicada by the following steps: cleaning the cicada, mincing the cicada into meat paste, adding Protamex compound protease for enzymolysis, wherein the enzymolysis conditions are as follows: the pH value is 6.8-7.2, the enzymolysis temperature is 42-47 DEG C, and the enzymolysis time is 7-9 hours; after the enzymolysis is finished, heating to inactivate the compound protease, and cooling to the room temperature; after the cooling, carrying out centrifugation at a rotation speed of 8000rpm-10000rpm for 20-30 minutes, extracting supernatant, and carrying out freeze drying, so as to obtain freeze-dried powder; dissolving the freeze-dried powder with ultrapure water, separating obtained enzymolysis polypeptide by virtue of ultrafiltration membranes with different molecular weight cut-offs, and carrying out freeze-drying on components obtained through ultrafiltration, so as to obtain enzymolysis polypeptides with different molecular weights. According to the enzymolysis polypeptide, the proliferation of A549 cells of the lung adenocarcinoma can be restrained, the apoptosis of the A549 cells can be promoted, the growth of nude mice transplanted tumors of the A549 cells of the lung adenocarcinoma is remarkably inhibited, and drug resistance of the A549 cells of the lung adenocarcinoma to the enzymolysis polypeptide is unlikely to be produced; and toxicology researches prove that the enzymolysis polypeptide has no toxic and side effects.

The invention relates to a herba epimedii total flavonoid enzymatic product. Herba epimedii total flavonoid is generated through immobilized helicase, and the enzymatic product has higher antineoplastic activity than the herba epimedii total flavonoid archetype and free enzyme enzymatic product and has high oral absorptivity. The invention further discloses a preparing method of the enzymatic product. The immobilized enzyme is used for enzymolysis of herba epimedii total flavonoid, selected helicase is high in combining efficiency with a fixed carrier and high in stability, the enzymolysis conversion rate is large, the immobilized enzyme can be used circularly, resources can be saved, and green production is achieved. The invention further relates to application of the enzymatic product in antitumous effect, and the herba epimedii total flavonoid enzymatic product obtained through the technical scheme has a remarkable anti-proliferative effect on the human lung cancer cell A549, liver cancer HepG2 cell, breast cancer MCF-7 cell, cervical cancer Hela cell and can be used for treating the lung cancer, liver cancer, breast cancer and cervical cancer.